Compare MEI & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEI | FLGT |
|---|---|---|
| Founded | 1946 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 581.1M | 511.0M |
| IPO Year | 1994 | 2016 |
| Metric | MEI | FLGT |
|---|---|---|
| Price | $14.56 | $20.11 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $22.00 | N/A |
| AVG Volume (30 Days) | ★ 550.3K | 242.4K |
| Earning Date | 12-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | ★ 42.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $908,300,000.00 | $18,730,000.00 |
| Revenue This Year | $4.13 | $2.80 |
| Revenue Next Year | $5.76 | $15.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 11.24 | N/A |
| 52 Week Low | $4.88 | $13.46 |
| 52 Week High | $20.38 | $31.04 |
| Indicator | MEI | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 50.48 | 43.15 |
| Support Level | $13.22 | $19.35 |
| Resistance Level | $15.75 | $21.56 |
| Average True Range (ATR) | 1.01 | 0.92 |
| MACD | -0.04 | -0.21 |
| Stochastic Oscillator | 50.69 | 11.15 |
Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, with the majority of revenue from Europe, the Middle East & Africa (EMEA).
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.